Current status of autologous stem cell transplantation in relapsed and refractory Hodgkin's lymphoma

Item

http://www.wikidata.org/entity/Q35705317

description

2011 nî lūn-bûn

@nan

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

2011年论文

@zh

2011年论文

@zh-cn

name

Current status of autologous s ...... refractory Hodgkin's lymphoma

@ast

Current status of autologous s ...... refractory Hodgkin's lymphoma

@en

type

Item

label

Current status of autologous s ...... refractory Hodgkin's lymphoma

@ast

Current status of autologous s ...... refractory Hodgkin's lymphoma

@en

prefLabel

Current status of autologous s ...... refractory Hodgkin's lymphoma

@ast

Current status of autologous s ...... refractory Hodgkin's lymphoma

@en

P1476

Current status of autologous s ...... refractory Hodgkin's lymphoma

@en

P2093

Anna Colpo

http://www.w3.org/2001/XMLSchema#string

Ephraim Hochberg

http://www.w3.org/2001/XMLSchema#string

Yi-Bin Chen

http://www.w3.org/2001/XMLSchema#string

P2860

A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model.

Time-intensified dexamethasone/cisplatin/cytarabine: an effective salvage therapy with low toxicity in patients with relapsed and refractory Hodgkin's disease.

Gemcitabine, cisplatin and methylprednisolone chemotherapy (GEM-P) is an effective regimen in patients with poor prognostic primary progressive or multiply relapsed Hodgkin's and non-Hodgkin's lymphoma.

Gemcitabine, dexamethasone and cisplatin is an active and non-toxic chemotherapy regimen in relapsed or refractory Hodgkin's disease: a phase II study by the National Cancer Institute of Canada Clinical Trials Group.

Outpatient fractionated ifosfamide, carboplatin and etoposide as salvage therapy in relapsed and refractory non-Hodgkin's and Hodgkin's lymphoma.

Ifosfamide, gemcitabine, and vinorelbine: a new induction regimen for refractory and relapsed Hodgkin's lymphoma.

Gemcitabine, vinorelbine, and pegylated liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin's lymphoma: CALGB 59804.

Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma.

Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.

Sequential high-dose ifosfamide, carboplatin and etoposide with rituximab for relapsed Hodgkin and large B-cell non-Hodgkin lymphoma: increased toxicity without improvement in progression-free survival.

P304

80-90

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1634/THEONCOLOGIST.2011-0177

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2011-12-30T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

51973416

http://www.w3.org/2001/XMLSchema#string

P698

22210089

http://www.w3.org/2001/XMLSchema#string

P932

3267827

http://www.w3.org/2001/XMLSchema#string